New Paradigms Emerge for Translating Immunotherapy Into Broad Clinical Use

Jane de Lartigue, PhD
Published: Friday, Mar 14, 2014
Axel Hoos, MD, PhD,vice president of
Oncology R&D at GlaxoSmithKline Pharmaceuticals

Axel Hoos, MD, PhD

Although breakthrough successes are generating a renaissance for anticancer immunotherapies, the framework for translating promising research results into clinical practice remains very much under construction. As researchers work to build a foundation for widespread translation of immunotherapies, there is a growing appreciation that new approaches are needed to overcome the unique challenges that the development of such therapies pose.

Changing Drug Development While practicing oncologists are increasingly willing to embrace immunotherapies, the pathway to regulatory approval for those promising medicines has highlighted distinct development challenges. In the past, regulators applied methods used to assess conventional cytotoxic cancer therapies to immunotherapeutic agents, but now they are recognizing the unique biologic activity of these emerging drugs.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Publication Bottom Border
Border Publication